Journal
ANNALS OF ONCOLOGY
Volume 27, Issue 10, Pages 1966-1969Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdw288
Keywords
-
Categories
Ask authors/readers for more resources
The role of tumor PD-L1 expression was investigated across the nivolumab clinical development program. Phase III nivolumab trials have shown that patients with tumors not expressing PD-L1 may benefit; therefore, testing is not required to select patients for therapy. The Dako PD-L1 IHC 28-8 pharmDx assay may be used to determine tumor PD-L1 expression as a complementary and informative test.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available